Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

J Zhang, Y Zhang, J Wang, Y Xia, J Zhang… - Signal transduction and …, 2024 - nature.com
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

AD Bondarev, MM Attwood, J Jonsson… - British journal of …, 2021 - Wiley Online Library
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

HDAC6 as privileged target in drug discovery: A perspective

S Pulya, SA Amin, N Adhikari, S Biswas, T Jha… - Pharmacological …, 2021 - Elsevier
Abstract HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and
physiological functions. Besides histone modification, largely due to its cytoplasmic …

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

KJ Falkenberg, RW Johnstone - Nature reviews Drug discovery, 2014 - nature.com
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are
often caused by genetic defects that result in functional deregulation of epigenetic proteins …

Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives

R Jenke, N Reßing, FK Hansen, A Aigner, T Büch - Cancers, 2021 - mdpi.com
Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …

The epigenetics of aging and neurodegeneration

R Lardenoije, A Iatrou, G Kenis, K Kompotis… - Progress in …, 2015 - Elsevier
Epigenetics is a quickly growing field encompassing mechanisms regulating gene
expression that do not involve changes in the genotype. Epigenetics is of increasing …

Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations

VK Godena, N Brookes-Hocking, A Moller… - Nature …, 2014 - nature.com
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of
Parkinson's disease. LRRK2 is a multifunctional protein affecting many cellular processes …

Microtubule dysfunction: a common feature of neurodegenerative diseases

A Sferra, F Nicita, E Bertini - International journal of molecular sciences, 2020 - mdpi.com
Neurons are particularly susceptible to microtubule (MT) defects and deregulation of the MT
cytoskeleton is considered to be a common insult during the pathogenesis of …

HDAC6 inhibition restores TDP‐43 pathology and axonal transport defects in human motor neurons with TARDBP mutations

R Fazal, S Boeynaems, A Swijsen, M De Decker… - The EMBO …, 2021 - embopress.org
TDP‐43 is the major component of pathological inclusions in most ALS patients and in up to
50% of patients with frontotemporal dementia (FTD). Heterozygous missense mutations in …

Histone deacetylase 6 in health and disease

C Seidel, M Schnekenburger, M Dicato… - Epigenomics, 2015 - Taylor & Francis
Histone deacetylase (HDAC) 6 is a member of the class IIb HDAC family. This enzyme is
zinc-dependent and mainly localized in the cytoplasm. HDAC6 is a unique isoenzyme with …